Anti-D Rh immunoglobulin is indicated in which of the following situations?
What is the approximate recurrence risk for neural tube defects (NTDs) in a subsequent pregnancy, given that the first baby was born with an NTD?
What is the investigation of choice in a pregnant lady at 16 weeks of gestation with a history of delivering a baby with Down syndrome?
The most definitive clinical sign of pregnancy is:
What is the best approach to prevent congenital anomalies in infants of diabetic mothers?
In a normal Non-Stress Test (NST), what is the time period for observing two or three accelerations that peak at 15 bpm or more above the baseline?
Fetal pulsations are palpable at the earliest by which gestational age?
A 25-year-old woman presents for prenatal care at 28 weeks of gestation. She has had two previous pregnancies. What is her gravidity?
A 32-year-old woman, who has a 10-year-old child with Down syndrome, presents for prenatal care at 9 weeks of gestation. What advice should the doctor provide?
Osiander's sign is positive in which of the following conditions?
Explanation: **Explanation:** The primary objective of administering **Anti-D Rh immunoglobulin** is to prevent **Rh isoimmunization** (Rh sensitization). This condition occurs when an Rh-negative mother is exposed to Rh-positive fetal red blood cells, leading to the production of maternal antibodies that can cause Hemolytic Disease of the Fetus and Newborn (HDFN) in subsequent pregnancies. **Why Option D is Correct:** For Rh isoimmunization to occur, there must be **Rh feto-maternal incompatibility**. This is only possible if the **mother is Rh-negative** and the **father is Rh-positive**. If the father is Rh-positive, the fetus has a high probability (50-100%) of being Rh-positive. If fetal Rh-positive blood enters the maternal circulation (e.g., during delivery, miscarriage, or amniocentesis), the mother’s immune system recognizes the D-antigen as foreign and produces antibodies. Anti-D immunoglobulin neutralizes these fetal cells before sensitization occurs. **Why Other Options are Incorrect:** * **Options A & B:** If the **mother is Rh-positive**, she already possesses the D-antigen. Her immune system will not produce antibodies against it; therefore, there is no risk of isoimmunization. * **Option C:** If **both parents are Rh-negative**, the fetus will inevitably be Rh-negative. Since there is no D-antigen present in either the mother or the fetus, no immune response can be triggered. **High-Yield Clinical Pearls for NEET-PG:** * **Standard Dose:** 300 µg (1500 IU) is the standard dose, which can neutralize up to **30 ml** of fetal whole blood (or 15 ml of packed RBCs). * **Routine Timing:** In an unsensitized Rh-negative mother, Anti-D is typically given at **28 weeks** of gestation and again within **72 hours of delivery** (if the neonate is confirmed Rh-positive). * **Kleihauer-Betke Test:** Used to quantify the volume of feto-maternal hemorrhage to determine if additional doses of Anti-D are required. * **Indirect Coombs Test (ICT):** Must be **negative** in the mother before administering Anti-D; a positive ICT indicates that sensitization has already occurred, making Anti-D ineffective.
Explanation: **Explanation:** Neural tube defects (NTDs) follow a **multifactorial inheritance** pattern, meaning they result from a combination of genetic predisposition and environmental factors (most notably folic acid deficiency). **1. Why 4% is correct:** In the general population, the incidence of NTDs is approximately 0.1–0.2% (1 in 1,000). However, once a couple has one child with an NTD (anencephaly, spina bifida, or encephalocele), the risk of recurrence in a subsequent pregnancy increases significantly to approximately **3–5%** (standardized as **4%** for examination purposes). If two previous siblings are affected, the risk rises further to about 10%. **2. Why the other options are incorrect:** * **A (2%):** This underestimates the risk. While recurrence risks vary by geography, 3–5% is the globally accepted range for a single prior affected pregnancy. * **C (10%):** This is the approximate recurrence risk only after **two** previously affected siblings. * **D (20%):** This risk is too high for multifactorial inheritance and would be more characteristic of a high-penetrance autosomal dominant condition. **High-Yield Clinical Pearls for NEET-PG:** * **Prevention:** For the general population, the recommended dose of Folic Acid is **400 mcg (0.4 mg)/day** starting 1 month prior to conception. * **Secondary Prevention (High Risk):** For women with a **previous child with NTD**, the dose is increased to **4 mg/day** (10 times the standard dose). * **Screening:** Maternal Serum Alpha-Fetoprotein (MSAFP) is elevated in open NTDs. The best time for screening is **15–20 weeks** (ideal: 16–18 weeks). * **Diagnosis:** Targeted Level II Ultrasound is the gold standard for detecting structural defects.
Explanation: **Explanation:** The core concept here is distinguishing between **screening** and **diagnostic** tests in a high-risk pregnancy. A history of a prior child with Down syndrome significantly increases the risk of recurrence, necessitating a definitive diagnosis rather than a risk assessment. 1. **Why Amniocentesis is correct:** Amniocentesis is a **diagnostic test** that involves karyotyping fetal cells obtained from amniotic fluid. It is ideally performed between **15–20 weeks** of gestation. Since the patient is at 16 weeks, amniocentesis is the investigation of choice to provide a definitive chromosomal analysis with a high degree of accuracy (>99%). 2. **Why other options are incorrect:** * **Triple screen test:** This is a screening tool (measuring AFP, hCG, and uE3). In a patient with a high-risk history, screening is insufficient; a diagnostic test is required to confirm or rule out the condition. * **Chorionic Villous Sampling (CVS):** While CVS is also a diagnostic test, it is typically performed between **10–13 weeks**. At 16 weeks, the window for CVS has passed, making amniocentesis the appropriate choice. * **Ultrasound (USG):** USG can identify "soft markers" (like nuchal fold thickness) but cannot provide a definitive genetic diagnosis. **High-Yield Clinical Pearls for NEET-PG:** * **Timing is Key:** CVS (10–13 weeks), Amniocentesis (15–20 weeks), Cordocentesis (>20 weeks). * **Most common chromosomal abnormality** associated with increased maternal age or prior history is Trisomy 21 (Down syndrome). * **Amniocentesis Risk:** The procedure-related risk of miscarriage is approximately 0.5% (1 in 200). * **Quadruple Screen:** Includes Triple Screen + Inhibin A; it is the preferred screening test in the second trimester if invasive testing is declined.
Explanation: ### Explanation In Obstetrics, signs of pregnancy are categorized into **Presumptive, Probable, and Positive (Definitive)** signs. **1. Why Fetal Heart Sounds (FHS) is correct:** Fetal heart sounds are a **Positive sign** of pregnancy. Positive signs are those that can only be attributed to the presence of a fetus and are considered 100% diagnostic. Other positive signs include the visualization of the fetus on ultrasound and the perception of active fetal movements by an examiner. FHS can be heard via Doppler as early as 10–12 weeks and via Pinard stethoscope by 18–20 weeks. **2. Why the other options are incorrect:** * **Ballottement (A):** This is a **Probable sign**. While it suggests a floating body in the uterus, it can be mimicked by a large uterine fibroid or an ovarian cyst with ascites. * **Braxton Hicks contractions (C):** These are **Probable signs**. They are painless, irregular uterine contractions that can also occur in conditions like hematometra or soft uterine fibroids. * **Enlarged uterus (D):** This is a **Probable sign**. Uterine enlargement can be caused by pelvic tumors (fibroids), molar pregnancy, or adenomyosis, and is therefore not definitive. **Clinical Pearls for NEET-PG:** * **Presumptive signs:** Subjective symptoms felt by the mother (e.g., Amenorrhea, morning sickness, quickening, breast changes). * **Probable signs:** Objective signs noted by the examiner (e.g., Hegar’s sign, Goodell’s sign, Chadwick’s sign, positive urine hCG). * **Definitive/Positive signs:** Fetal heart sounds, fetal parts palpation (by examiner), and ultrasound evidence. * **High-yield:** The earliest definitive sign of pregnancy on ultrasound is the **Gestational Sac** (at 4.5–5 weeks).
Explanation: ### Explanation **1. Why Option D is Correct:** The critical period for fetal organogenesis occurs during the first **3–8 weeks** of gestation, often before a woman realizes she is pregnant. In diabetic mothers, hyperglycemia during this window is highly teratogenic, leading to a 4–8 fold increase in major structural malformations (most commonly cardiac and neural tube defects). Therefore, the **periconceptional period** (pre-conception and early first trimester) is the most vital time for tight glycemic control to normalize the intrauterine environment and reduce the risk of congenital anomalies to near-baseline levels. **2. Why Other Options are Incorrect:** * **Option A:** Glyburide is generally not the first-line treatment in pre-gestational diabetes. Discontinuing insulin in favor of oral agents often leads to suboptimal control, increasing the risk of anomalies. * **Option B:** While switching to insulin is standard practice, limiting it "until 36 weeks" is incorrect. Tight control must be maintained throughout the entire pregnancy to prevent macrosomia and stillbirth, and specifically *before* conception to prevent anomalies. * **Option C:** Insulin infusion during labor prevents **neonatal hypoglycemia** by stabilizing maternal glucose levels at delivery; however, it has no impact on preventing congenital anomalies, which are established in the first trimester. **3. High-Yield Clinical Pearls for NEET-PG:** * **Most Common Anomaly:** Ventricular Septal Defect (VSD) and other cardiac malformations. * **Most Specific Anomaly:** **Caudal Regression Syndrome** (Sacral agenesis) is highly characteristic of diabetic embryopathy. * **Target HbA1c:** Ideally, HbA1c should be **<6.5%** (or <6.0% if achievable without hypoglycemia) prior to conception. * **Screening:** Diabetic mothers require a **Fetal Echocardiogram** (at 18–22 weeks) in addition to a Level II anomaly scan.
Explanation: ### Explanation **1. Why Option C (20 minutes) is Correct:** A Non-Stress Test (NST) evaluates fetal well-being by observing the fetal heart rate (FHR) response to fetal movement. A **Reactive (Normal) NST** is defined by the presence of **two or more accelerations** within a **20-minute window**. An acceleration is defined as a peak of at least **15 beats per minute (bpm)** above the baseline, lasting for at least **15 seconds** (the "15x15" rule). This indicates a functional fetal autonomic nervous system and adequate oxygenation. **2. Why the Other Options are Incorrect:** * **A (3 minutes) & B (15 minutes):** These durations are too short. Fetal sleep cycles can last up to 40 minutes; therefore, a short observation window might result in a false-positive "non-reactive" result simply because the fetus is sleeping. * **D (60 minutes):** While an NST can be extended to 40 or 60 minutes if the initial 20-minute period is non-reactive (to account for fetal sleep), the standard diagnostic window for defining a reactive test is 20 minutes. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "15x15" Rule:** For pregnancies >32 weeks, accelerations must be ≥15 bpm for ≥15 seconds. For **preterm fetuses (<32 weeks)**, the criteria are lower: **10 bpm for 10 seconds**. * **Non-Reactive NST:** If criteria are not met within 40 minutes, the test is non-reactive. The next step is usually a **Biophysical Profile (BPP)** or a **Contraction Stress Test (CST)**. * **Most Common Cause of Non-Reactive NST:** Fetal sleep cycle. * **Vibroacoustic Stimulation (VAS):** Can be used to "wake" the fetus and shorten the time to a reactive result.
Explanation: **Explanation:** The correct answer is **20 weeks**. This question refers to the clinical sign known as **internal ballottement** or the manual palpation of fetal parts and movements through the maternal abdominal wall. **1. Why 20 weeks is correct:** By the 20th week of gestation (mid-pregnancy), the fetus has grown sufficiently in size and the volume of amniotic fluid is adequate to allow fetal parts to be felt through the abdominal wall. At this stage, the fundal height typically reaches the level of the umbilicus, making the uterus easily accessible for palpation of fetal movements and "fetal quickening" (maternal perception) is well-established. **2. Analysis of Incorrect Options:** * **16 weeks:** At this stage, the uterus is midway between the symphysis pubis and the umbilicus. While the fetus is moving, it is generally too small and the uterus is too low for distinct fetal pulsations/parts to be palpated externally by a clinician. * **18 weeks:** This is the typical time for **Quickening** in primigravida mothers, but clinical palpation of fetal parts by an examiner is usually not reliable until the 20th week. * **28 weeks:** By this time, fetal parts are very easily felt, and Leopold maneuvers can be performed to determine fetal lie and presentation. However, this is much later than the "earliest" possible time. **High-Yield Clinical Pearls for NEET-PG:** * **Quickening:** Perceived at 18 weeks in primigravida and 16 weeks in multigravida. * **Fetal Heart Sounds (FHS):** Can be heard by Doppler at 10–12 weeks and by Pinard stethoscope at 18–20 weeks. * **Fundal Height:** At 12 weeks (Symphysis Pubis), 20–22 weeks (Umbilicus), and 36 weeks (Xiphisternum). * **Internal Ballottement:** Can be elicited between 16–28 weeks.
Explanation: ### Explanation **Concept:** In obstetrics, **Gravidity (G)** refers to the total number of times a woman has been pregnant, regardless of the duration or the outcome of those pregnancies (e.g., live birth, miscarriage, abortion, or ectopic pregnancy). The current pregnancy is always included in this count. **Why G3 is Correct:** The patient is currently pregnant (1) and has a history of two previous pregnancies (2). * **Calculation:** 2 (previous) + 1 (current) = **G3**. **Analysis of Incorrect Options:** * **A. Nulligravida:** This term describes a woman who has never been pregnant. * **B. G1 (Primigravida):** This describes a woman who is pregnant for the first time. * **C. G2:** This would be correct if she had only one previous pregnancy. Since she has had two, this undercounts her total. **Clinical Pearls for NEET-PG:** * **Twins/Multiples:** A multiple gestation (twins, triplets) counts as **one** single gravidity and **one** single parity. * **Parity (P):** Refers to the number of pregnancies that have reached the age of viability (traditionally 24 weeks in many guidelines, though 20-22 weeks is often used in international scoring). Parity does not change until the current pregnancy ends. * **GTPAL System:** For more detailed coding, remember: **G**ravidity, **T**erm births, **P**reterm births, **A**bortions/Miscarriages, and **L**ive children. * **High-Yield Fact:** If a woman is currently pregnant, her Gravidity is always at least 1 higher than her Parity (unless she has never reached viability in any previous pregnancy).
Explanation: ### Explanation **1. Why Option C is Correct:** The patient has a significant risk factor: a **previous child with Down syndrome (Trisomy 21)**. This increases the recurrence risk for chromosomal abnormalities in subsequent pregnancies, regardless of maternal age. To provide a definitive diagnosis, a **diagnostic (invasive) test** is required rather than a screening test. Since the patient is currently at **9 weeks of gestation**, Chorionic Villus Sampling (CVS) is the most appropriate next step as it can be performed between **10–13 weeks**, allowing for an earlier diagnosis compared to amniocentesis (usually performed after 15 weeks). **2. Why Other Options are Incorrect:** * **Option A:** Blood investigations (like the Double Marker or Quadruple Screen) and NIPT are **screening tests**. They provide a risk probability but cannot definitively diagnose a chromosomal condition. * **Option B:** Ultrasound findings (like increased Nuchal Translucency) are **soft markers** or screening tools. While they suggest a higher risk, they are not confirmatory for Down syndrome. * **Option D:** While maternal age ≥35 is a classic risk factor, a **prior history of an affected child** is an independent indication for invasive prenatal diagnosis, regardless of the mother's current age. **3. Clinical Pearls for NEET-PG:** * **Definitive Diagnosis:** Only invasive tests (CVS or Amniocentesis) providing a **Karyotype** or **CMA** (Chromosomal Microarray) are diagnostic. * **Timing:** CVS (10–13 weeks); Amniocentesis (15–20 weeks). * **Recurrence Risk:** After one child with Trisomy 21, the recurrence risk is approximately **1%** or the age-related risk (whichever is higher). * **Most Common Marker:** Increased **Nuchal Translucency (NT)** on a 11–13.6 week scan is the most sensitive ultrasound marker for Down syndrome.
Explanation: **Explanation:** **Osiander’s sign** is a clinical sign of early pregnancy characterized by **increased pulsation felt through the lateral vaginal fornices**. This occurs due to increased vascularity and pelvic congestion as the uterine artery supply to the gravid uterus intensifies. It typically becomes palpable around the **8th week** of gestation. **Why the correct answer is right:** * **A. First trimester of pregnancy:** During the first trimester, the body undergoes significant hemodynamic changes. The marked increase in blood flow to the pelvic organs to support the developing embryo results in the characteristic pulsations felt during a bimanual examination. **Why the incorrect options are wrong:** * **B. Fibroid:** While large fibroids can be vascular, they do not typically produce the rhythmic, synchronized arterial pulsations characteristic of Osiander’s sign. * **C. Hydatidiform mole:** Although a molar pregnancy is a gestational trophoblastic disease, the clinical signs usually emphasize a "doughy" feel of the uterus or "snowstorm" appearance on USG rather than the specific lateral fornix pulsations. * **D. Abdominal pregnancy:** In extrauterine pregnancies, the vascular supply is disorganized and does not follow the typical uterine artery hypertrophy seen in intrauterine pregnancies, making this sign absent. **High-Yield Clinical Pearls for NEET-PG:** * **Goodell’s Sign:** Softening of the cervix (6th week). * **Ladin’s Sign:** Softening in the anterior midline of the uterus at the cervico-uterine junction (6th week). * **Hegar’s Sign:** Softening of the lower uterine segment; the upper body and cervix feel like two separate regions (6–10 weeks). * **Chadwick’s Sign:** Bluish discoloration of the cervix, vagina, and labia due to venous congestion (8th week). * **Piscacek’s Sign:** Asymmetrical enlargement of the uterus if implantation occurs near a uterine horn.
Preconception Counseling
Practice Questions
Pregnancy Diagnosis and Dating
Practice Questions
Routine Antenatal Assessments
Practice Questions
Maternal Physiological Changes
Practice Questions
Nutrition in Pregnancy
Practice Questions
Screening Tests in Pregnancy
Practice Questions
Fetal Growth Assessment
Practice Questions
High-Risk Pregnancy Identification
Practice Questions
Antenatal Complications Management
Practice Questions
Psychosocial Aspects of Pregnancy
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free